Osteoporosis, is the most common bone disorder worldwide characterized by low bone
mineral density, leaving affected bones vulnerable to fracture. Bone homeostasis depends …

Objective To review the comparative effectiveness of osteoporosis treatments, including the
bone anabolic agents, abaloparatide and romosozumab, on reducing the risk of fractures in …

To evaluate whether treatment sequence affects romosozumab response, this analysis
reviewed studies where romosozumab was administered before or following an …

Osteoporosis is a systemic metabolic disease, mainly characterized by reduced bone
mineral density and destruction of bone tissue microstructure. However, the molecular …

Osteoporosis is an age-related disorder characterized by progressive bone loss and
impaired bone regeneration following surgery. The key to the treatment of osteoporosis is …

Osteoporosis is a systemic skeletal disease characterized by decreased bone mass,
destruction of bone microstructure, raised bone fragility, and enhanced risk of fractures. The …

Osteoporosis (OP) is a major global health concern, with aging being one of the most
important risk factors. Osteoarthritis (OA) is also an age-related disorder. Patients with OP …

Increased understanding of the Wnt signaling pathway has led to the development of
romosozumab, one of the most potent osteoanabolic agents to date for osteoporosis …

Reducing fracture risk is the objective of osteoporosis treatment. Bone-forming osteoporosis
drugs increase bone mass, restore bone microarchitecture, and reduce fracture risk more …

Bone fragility is the susceptibility to fracture even for common loads because of structural,
architectural, or material alterations of bone tissue that result in poor bone strength. In …